Light Mode
$14.33 ↑ +0.60 (+4.37%) Trading Up from the previous close of $13.73, and at the day’s high of $14.33
+2.69 (+23.06%) / 6M
Momentum, market sentiment, and recent alerts
SHMXY reads n/a: the 12-month move is -13.5%.
No alerts for SHMXY in the last day.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Shimadzu Corp. engages in the manufacture and sale of testing, measuring, medical, aircraft and analytical instruments. It operates through the following segments: Analytical Instruments, Medical Systems, Aircraft Equipment, Industrial Machinery & Equipment, and Others. The Analytical Instruments segment handles the general analytical and environmental measurement instruments such as mass spectrometers, chromatographs, spectrophotometers, surface analysis and observation systems, water quality analyzers, and continuous emission monitoring systems. The Medical System segment offers diagnostic systems and services to medical facilities such as fluoroscopy, angiography, radiography, near-infrared imaging, and medical information systems. The Aircraft Equipment segment provides aircraft and ground support equipment which includes flight control, air management, cockpit display systems, aircraft equipment functional testers, and aircraft medical training equipment. The Industrial Machinery & Equipment segment offers advanced-level manufacturing and testing equipment for the industrial field such as turbo molecular pumps, anti-reflective coating systems for solar cells, hydraulic gear pumps, power packages, diffraction gratings, and laser modules. The Others segment handles the leasing and management of real estate, software development, product design, and pavement construction business. The company was founded by Genzo Shimadzu Sr. on March 31, 1875 and is headquartered in Kyoto, Japan.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.